HCV / Hepatitis

A hepatitis A outbreak in Hawaii has reached more than 200 cases.

In response to an increase of hepatitis C cases in Rhode Island that have resulted in hospitalizations and deaths, the Rhode Island Department of Health and the Rhode Island Public Health Institute have worked together to compose their first ever, comprehensive epidemiological report.

Collateral damage from the ongoing opioid abuse epidemic in the United States continues to plague many rural communities across the country, with recent reports suggesting it is likely behind clusters of HIV cases in these areas.

Liver fibrosis and subsequent cirrhosis result from chronic damage to the liver that is caused by most types of chronic liver disease, including chronic hepatitis C virus infection and alcohol abuse.

World Hepatitis Day aims to increase awareness and understanding of viral hepatitis. The ECDC discusses Europe’s plan to eliminate hepatitis by 2030.

The Hawaii State Department has confirmed an open investigation of the hepatitis A infection in Oahu, Hawaii.

The US Food and Drug Administration just approved a new regimen to treat the six major forms of chronic hepatitis C (HCV).

A recent study has estimated the seroprevalence of hepatitis C virus (HCV) infection to be 0.5% in the antenatal population.

Hepatitis C virus (HCV) cure when using direct-acting antiviral (DAA) agents in human immunodeficiency virus (HIV)-coinfected patients is lower in real-world settings than when patients are enrolled in clinical trials, a new study has found.

A recent study in treatment-naïve patients with chronic hepatitis C virus (HCV) infection has shown that ledipasvir/sofosbuvir (LDV/SOF) combination therapy produces similar sustained virologic response (SVR) rates in clinical trial-based studies and real-world studies.

Charitha Gowda, MD, MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the impact direct-acting antivirals have had on patients’ adherence to their drug regimen when treating hepatitis C.

Contagion™ Editorial Board member, Charitha Gowda, MD, MPH breaks down the World Health Organization hepatitis C (HCV) guidelines update, and reminds healthcare professionals to build on these guidelines to advocate for the most effective and safest treatment options for our individual patients and all patients worldwide.

Charitha Gowda, MD, MPH, Infectious diseases physician at Penn Presbyterian Medical Center explains how the treatment regimen for treating those with acute hepatitis C differs from chronic hepatitis C.

Charitha Gowda, MD, MPH, Infectious diseases physician at Penn Presbyterian Medical Center explains the process for the evaluation of hepatitis C, leading up to treatment.

Charitha Gowda, MD, MPH, discusses the current and upcoming methods to prevent hepatitis C.

The ongoing refugee crisis facing European countries as a result of conflicts in the Middle East presents a potential public health challenge to governments already struggling with the influx of hundreds of new migrants on a daily basis.

Charitha Gowda, MD, MPH, explains why we see such a high incidence of HIV / HCV coinfection.

In a recent study of 1,812 human immunodeficiency virus (HIV)-infected individuals in sub-Saharan Africa, researchers found that none of these individuals had confirmed hepatitis C virus replication.

Global pharmaceutical company, AbbVie, announced the approval of a supplemental new drug application for VIEKIRA PAK® without ribavirin in chronic hepatitis C patients with genotype 1b (HCV-1b) and compensated cirrhosis.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the recent decision from The Department of Veterans Affairs (VA) to supply hepatitis C (HCV) treatment to all veterans, regardless of disease stage.

Researchers from the National Academies of Sciences, Engineering, and Medicine report that there is a possibility of eliminating the transmission of both Hepatitis B and C in the United States.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center, explains the barriers to hepatitis C (HCV) treatment.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the preferred treatment method for hepatitis C.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the current treatment methods for hepatitis C.

Hepatitis C has been referred to as a silent killer. As a result, Charitha Gowda, MD, MPH, provides information on the newest diagnostic tests available for hepatitis C.

Charitha Gowda, MD, MPH addresses concerns that hepatitis could be transmitted via mosquitoes.

Charitha Gowda, MD, MPH, explains the ways that hepatitis A, B, and C are transmitted and recent discoveries in the modes of transmission.

An increase in funding from Congress, in addition to a decrease in drug prices, will allow the VA to finance medical care for all hepatitis C patients, regardless of the stage of the disease, for fiscal year 2016.

People with the human immunodeficiency virus (HIV) are at a higher risk of having hepatitis C (HCV), however, less than two-thirds of patients are being screened regularly.

The FDA approved label warning changes for two Gilead Sciences hepatitis C drugs after one person died and nine others had serious reactions when the drugs were coadministered with amiodarone, a drug used to treat irregular heartbeat.